In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reapplix APS

www.reapplix.com

Latest From Reapplix APS

Reapplix Eyes US Market With Trial Results For Wound-Healing Tech

Following the presentation of results from a randomized trial, Reapplix is ramping up its commercial operations with the hire of a new US president to lead sales of its wound-healing platform, LeucoPatch.

Clinical Trials Research & Development

Reapplix Seals In More Funding For Diabetic Foot Ulcer Patch

Reapplix, an emerging autologous cell-based wound therapy specialist, has secured additional funding that will take the company through the next year before it gets “market-ready” to launch its diabetic foot ulcer treatment in the US and EU.

Diabetic Care Wound Management

Advanced Wound Care: Untapped Opportunities

Mega-deals and innovative technologies have transformed advanced wound care into a robust, high-tech market in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.

Medical Device

Advanced Wound Care – Untapped Opportunities

With worldwide revenues projected to reach $6 billion in 2015, mega-deals and innovative game-changing technologies have transformed the advanced wound care market into a robust, high-tech arena in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.

Medical Device Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
  • Therapeutic Areas
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Reapplix APS
  • Senior Management
  • Niels E Holm, PhD, CEO
    Rasmus Lundquist, CSO
  • Contact Info
  • Reapplix APS
    Phone: 88 16 80 66
    Blokken 45
    Birkerød, 3460
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register